培养基中血清的物种来源会影响二氧化硅纳米颗粒对HepG2细胞的体外毒性。

The species origin of the serum in the culture medium influences the in vitro toxicity of silica nanoparticles to HepG2 cells.

作者信息

Pisani Cédric, Rascol Estelle, Dorandeu Christophe, Gaillard Jean-Charles, Charnay Clarence, Guari Yannick, Chopineau Joël, Armengaud Jean, Devoisselle Jean-Marie, Prat Odette

机构信息

Institut Charles Gerhardt de Montpellier, MACS, UMR 5253 CNRS-ENSCM-UM, Place Eugène Bataillon, Montpellier, France.

CEA, Direction de la Recherche Fondamentale-BIAM, Site de Marcoule, Bagnols-sur-Cèze, France.

出版信息

PLoS One. 2017 Aug 10;12(8):e0182906. doi: 10.1371/journal.pone.0182906. eCollection 2017.

Abstract

The formation of a protein corona around nanoparticles can influence their toxicity, triggering cellular responses that may be totally different from those elicited by pristine nanoparticles. The main objective of this study was to investigate whether the species origin of the serum proteins forming the corona influences the in vitro toxicity assessment of silica nanoparticles. Coronas were preformed around nanoparticles before cell exposures by incubation in fetal bovine (FBS) or human (HS) serum. The compositions of these protein coronas were assessed by nano-LC MS/MS. The effects of these protein-coated nanoparticles on HepG2 cells were monitored using real-time cell impedance technology. The nanoparticle coronas formed in human or fetal bovine serum comprised many homologous proteins. Using human compared with fetal bovine serum, nanoparticle toxicity in HepG2 cells decreased by 4-fold and 1.5-fold, when used at 50 and 10μg/mL, respectively. It is likely that "markers of self" are present in the serum and are recognized by human cell receptors. Preforming a corona with human serum seems to be more appropriate for in vitro toxicity testing of potential nanocarriers using human cells. In vitro cytotoxicity assays must reflect in vivo conditions as closely as possible to provide solid and useful results.

摘要

纳米颗粒周围蛋白质冠层的形成会影响其毒性,引发的细胞反应可能与原始纳米颗粒引发的反应完全不同。本研究的主要目的是调查形成蛋白质冠层的血清蛋白的物种来源是否会影响二氧化硅纳米颗粒的体外毒性评估。在细胞暴露前,通过在胎牛血清(FBS)或人血清(HS)中孵育,使纳米颗粒预先形成蛋白质冠层。通过纳米液相色谱串联质谱法(nano-LC MS/MS)评估这些蛋白质冠层的组成。使用实时细胞阻抗技术监测这些蛋白质包被的纳米颗粒对HepG2细胞的影响。在人血清或胎牛血清中形成的纳米颗粒蛋白质冠层包含许多同源蛋白。当分别以50μg/mL和10μg/mL的浓度使用时,与胎牛血清相比,使用人血清时HepG2细胞中的纳米颗粒毒性分别降低了4倍和1.5倍。血清中可能存在“自身标记物”,并被人类细胞受体识别。用人血清预先形成蛋白质冠层似乎更适合使用人类细胞对潜在纳米载体进行体外毒性测试。体外细胞毒性测定必须尽可能紧密地反映体内情况,以提供可靠且有用的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8d8/5552166/a631160a33b7/pone.0182906.g001.jpg

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索